Low dose irradiation

RADIATION3 trials

Sponsors

National Heart, Lung, and Blood Institute (NHLBI), Sheba Medical Center

Conditions

Metastatic or Locally Advanced NSCLCSickle Cell AnemiaStage IV Pancreatic Cancer

Phase 1

Haploidentical PBMC Transplant for Severe Congenital Anemias

Active, not recruitingNCT00977691

National Heart, Lung, and Blood Institute (NHLBI)Sickle Cell Anemia

Start: 2009-12-14End: 2026-09-10Updated: 2026-04-23

Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer

Sheba Medical CenterStage IV Pancreatic Cancer

Start: 2022-01-25End: 2024-07-01Target: 10Updated: 2023-11-28

Phase 2

Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy

Active, not recruitingNCT05000710

Sheba Medical CenterMetastatic or Locally Advanced NSCLC

Start: 2021-12-09End: 2026-12-31Target: 29Updated: 2024-12-05

Related Papers

Concomitant radiotherapy, tremelimumab, and durvalumab for advanced NSCLC patients progressing on first-line immunotherapy: A phase 2 study (CORAL-Lung).

Journal of Clinical Oncology2026-05-28

Hematopoietic Stem Cell Transplant and Brain Volume Changes in Adults With Sickle Cell Disease.

2026-05-14

Nonmyeloablative pentostatin-cyclophosphamide preconditioning improves rates of engraftment in adults undergoing haploidentical HCT for sickle cell disease.

2026-03-23

Impact of pre-transplant bone marrow cellularity and fibrosis on post-transplant outcomes in sickle cell disease

Blood2025-11-03

The impact of hematopoietic cell transplantation on sickle cell hepatopathy and vice versa

Blood2025-11-03

Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT

Blood Advances2017-04-19103 citations